Long-term cost-effectiveness of tight control for Crohn-s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial - Panaccione, R.; Colombel, J-F.; Bossuyt, P.; Baert, F.; Vanasek, T.; Danalioglu, A.; Novacek, G.; Armuzzi, A.; Reinisch, W.; Johnson, S.; Buessing, M.; Neimark, E.; et al. (My University, 2018)